This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Agenus (AGEN) to Focus on BOT/BAL Candidate, Stock Falls 7%
by Zacks Equity Research
Agenus (AGEN) to halt all other developmental programs to focus on its BOT/BAL program. The company plans to cut its workforce by 25%.
5 Defensive Stocks to Buy Amid Lingering Market Volatility
by Ritujay Ghosh
Volatility has gripped Wall Street again. So, investing in defensive stocks like McKesson Corporation (MCK), Entergy Corporation (ETR), PepsiCo, Inc. (PEP), Johnson & Johnson (JNJ) and Atmos Energy Corporation (ATO) is a safe bet.
Is iShares Core High Dividend ETF (HDV) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for HDV
Is WisdomTree U.S. Quality Dividend Growth ETF (DGRW) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for DGRW
Zoetis' (ZTS) Companion Animal Products to Boost Revenues
by Zacks Equity Research
Zoetis' (ZTS) revenues are expected to boost the pet care and livestock product sales in the quarters ahead. Disease outbreaks and potential supply challenges hurt prospects.
Will Keytruda Remain Merck's (MRK) Key Top-Line Driver?
by Zacks Equity Research
With continued label expansion into new indications, particularly earlier-line launches, Merck's (MRK) Keytruda is expected to remain a key top-line driver.
Krystal (KRYS) Up 5% on Sale of FDA's Priority Review Voucher
by Zacks Equity Research
Krystal (KRYS) announces the sale of its priority review voucher for a consideration of $100 million. The stock of the company rises 5.2% on the news.
J&J (JNJ) to Keep 9.5% Stake in Kenvue Post Share Exchange
by Zacks Equity Research
J&J's (JNJ) offer to exchange its shares for the shares of Kenvue, its recently-separated consumer healthcare business, gets oversubscribed. The exchange ratio is 8.0324 for every share of J&J.
Armata Pharma (ARMP) Stock Surges 130% in a Month: Here's Why
by Zacks Equity Research
Armata Pharma (ARMP) stock skyrockets 130% in a month due to encouraging progress of the company's pathogen-targeting natural and synthetic phage candidates.
5 Blue-Chip Stocks for a Stable Portfolio Amid Volatility
by Nalak Das
We have narrowed our search to five blue-chip such stocks with strong growth potential for the rest of 2023. These are: WMT, JPM, JNJ, CAT, MCD.
Zacks Industry Outlook Highlights Eli Lilly, J&J, Novo Nordisk, Novartis and AstraZeneca
by Zacks Equity Research
Eli Lilly, J&J, Novo Nordisk, Novartis and AstraZeneca are part of the Zacks Industry Outlook article
Merck's (MRK) Welireg Meets Renal Cell Carcinoma Study Goals
by Zacks Equity Research
Based on interim data from a late-stage study, Merck's (MRK) Welireg achieves statistically significant improvements in one of the study's dual endpoints of progression-free survival.
Belite Bio (BLTE) Stock Surges 72% in a Month: Here's Why
by Zacks Equity Research
Belite Bio (BLTE) rises 72% in a month due to encouraging progress on the development of the company's lead product candidate Tinlarebant, which is being developed to treat several eye diseases.
Momentum Mondays: Stocks Setting up for an Epic Dip Buying Opportunity?
by Ethan Feller
Want to start the week ahead of the pack? Check out Momentum Mondays!
5 Large Drug Stocks to Watch as New Drug Approvals & M&A Gain Pace
by Kinjel Shah
Drug, biotech companies are likely to see significant innovation. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), J&J (JNJ), Novo Nordisk (NVO), Novartis (NVS) and AstraZeneca (AZN) are worth retaining in your portfolio.
Should Schwab U.S. Large-Cap Value ETF (SCHV) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for SCHV
Amphastar Pharma (AMPH) Stock Skyrockets 89% YTD: Here's Why
by Zacks Equity Research
Amphastar Pharma (AMPH) shares are up 89.1% year to date due to the acquisition of Baqsimi from Lilly. The company also receives FDA approval for Naloxone.
Here's Why You Should Add Dr. Reddy's (RDY) to Your Portfolio
by Zacks Equity Research
Dr. Reddy's (RDY) continues to enjoy a strong foothold in the global generics market due to its deep generic drugs pipeline. The company is also looking to strengthen its biosimilars portfolio.
Pharma Stock Roundup: FDA Okays PFE & JNJ Drugs, EU Approves ABBV's Migraine Drug
by Kinjel Shah
FDA approves Pfizer's (PFE) Elrexfio (elranatamab) for RRMM and J&J's (JNJ) oral combination tablet, Akeega to treat BRCA-positive mCRPC. European Commission approves AbbVie's (ABBV) Aquipta for migraine.
Here's Why it is a Good Time to Buy J&J's (JNJ) Stock Now
by Zacks Equity Research
J&J's (JNJ) Pharma sales are being driven by key drugs like Darzalex and new products. J&J's Pharma and MedTech units are likely to continue to drive sales growth in 2023.
AbbVie (ABBV) Gets EU Approval for Migraine Prevention Drug
by Zacks Equity Research
Following the approval, AbbVie's (ABBV) Aquipta is the first and the only oral CGRP receptor antagonist approved in the EU to prevent episodic and chronic migraines.
Eli Lilly (LLY) Stock Up Almost 50% Year to Date: Here's Why
by Zacks Equity Research
Sales of Lilly's (LLY) new drug, Mounjaro are already benefiting from strong demand trends. Lilly expects regulatory decisions for some key pipeline candidates this year, which are key to growth.
Seagen's (SGEN) Breast Cancer Study on Tuksya Combo Meets Goal
by Zacks Equity Research
Seagen (SGEN) announces positive top-line results from its breast cancer study evaluating Tuksya in combination with Roche's Kadcyla.
Kodiak (KOD) Q2 Earnings Miss, New Lead Candidate in Focus
by Zacks Equity Research
Kodiak (KOD) reports weaker-than-expected results in second-quarter 2023. The company also provides an update on the status of its pipeline after discontinuing the tarcocimab program.
Pfizer's (PFE) New Multiple Myeloma Drug Elrexfio Gets FDA Nod
by Zacks Equity Research
The FDA's accelerated approval of Pfizer's (PFE) new multiple myeloma drug Elrexfio/elranatamab is based on data from the pivotal phase II MagnetisMM-3 study.